EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk

Robert J MacInnis iD, Mark A Jenkins iD, Roger L Milne iD, Esther M John iD, Mary B Daly, Irene L Andrulis iD, Sarah V Colonna iD, Kelly-Anne Phillips iD, kConFab Investigators, Loic Le Marchand iD, Polly A Newcomb, Amanda I Phipps und 10 weitere

JNCI Cancer Spectrum · 2025

DOI: 10.1093/jncics/pkae121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Robert J MacInnis und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Epidemiology Division, Cancer Council Victoria, East Melbourne, VIC 3002, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Colorectal Neoplasms, Menopause, Estrogen Replacement Therapy. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, US government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Menopausal users of hormone replacement therapy (HRT) are at increased breast cancer risk and decreased colorectal cancer (CRC) risk compared with individuals who have never used HRT, but these opposing associations may differ by familial risk of breast cancer and CRC. We harmonized data from 3 cohorts and generated separate breast cancer and CRC familial risk scores based on cancer family history. We defined moderate or strong family history as a risk score of 0.4 or higher, where 0.4 was equivalent to a 50-year-old woman with 1 parent diagnosed with either breast cancer or CRC at 55 years of age. Of 24 486 women assessed, 1243 and 405 were diagnosed with incident breast cancer and CRC, respectively. For breast cancer, menopausal HRT ever use versus never use hazard ratios were 1.27 (95% CI = 1.11 to 1.45) for a breast cancer familial risk score below 0.4 and 1.01 (95% CI = 0.82 to 1.25) for a breast cancer familial risk score of 0.4 or higher (Pdifference = .08). For CRC, menopausal HRT hazard ratios were 0.63 (95% CI = 0.50 to 0.78) for a CRC familial risk score below 0.4 and 1.21 (95% CI = 0.73 to 2.00) for a CRC familial risk score of 0.4 or higher (Pdifference = .03). Associations with menopausal HRT use that apply to the general population may not hold for women at moderate or strong familial risk of these cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsColorectal NeoplasmsMenopauseEstrogen Replacement TherapyHumansFemaleMiddle AgedHormone Replacement TherapyProportional Hazards ModelsRisk FactorsAgedRisk AssessmentGenetic Predisposition to Disease

Autor:innen und Institutionen

  • Cancer Epidemiology Division, Cancer Council Victoria, East Melbourne, VIC 3002, Australia.
  • Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, VIC 3053, Australia.
  • Cancer Research Centre, University of Melbourne, Parkville, VIC 3053, Australia.
  • Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3800, Australia.
  • Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA 94305, United States.
  • Department of Medicine (Oncology), Stanford University School of Medicine, Stanford, CA 94305, United States.

ORCID-Profile: Robert J MacInnis, Mark A Jenkins, Roger L Milne, Esther M John, Irene L Andrulis, Sarah V Colonna, Kelly-Anne Phillips, Loic Le Marchand, Stephanie L Schmit, Finlay A Macrae, Daniel D Buchanan, Steven Gallinger, Rish K Pai, Niloy J Samadder, Graham G Giles, Melissa C Southey, John L Hopper, Mary Beth Terry

Förderung

  • NCI NIH HHS
  • US government

Zitieren

APA

MacInnis, R. J., Jenkins, M. A., Milne, R. L., John, E. M., Daly, M. B., Andrulis, I. L., Colonna, S. V., Phillips, K. A., kConFab Investigators, Le Marchand, L., Newcomb, P. A., Phipps, A. I., Schmit, S. L., Macrae, F. A., Buchanan, D. D., Gallinger, S., Pai, R. K., Samadder, N. J., Giles, G. G., …, & Terry, M. B. (2025). Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae121

Vancouver

MacInnis RJ, Jenkins MA, Milne RL, John EM, Daly MB, Andrulis IL, et al. Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkae121

BibTeX
@article{MacInnis2025,
  author = {MacInnis, Robert J and Jenkins, Mark A and Milne, Roger L and John, Esther M and Daly, Mary B and Andrulis, Irene L and Colonna, Sarah V and Phillips, Kelly-Anne and kConFab Investigators, kConFab Investigators and Le Marchand, Loic and Newcomb, Polly A and Phipps, Amanda I and Schmit, Stephanie L and Macrae, Finlay A and Buchanan, Daniel D and Gallinger, Steven and Pai, Rish K and Samadder, Niloy J and Giles, Graham G and Southey, Melissa C and Hopper, John L and Terry, Mary Beth},
  title = {Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk},
  journal = {JNCI Cancer Spectrum},
  year = {2025},
  doi = {10.1093/jncics/pkae121}
}
Kostenlos starten →